121 results about "Pulmonary disorders" patented technology

The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and / or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).

The invention discloses a method and a system for extracting a region of interest of a lung disease pathology full-slice image, relates to extraction of a region of interest, and aims to solve the technical problem of low accuracy of region of interest extraction in the prior art. Comprising the following steps: acquiring lung image data and calculating a semantic similarity score and a visual representation vector of each block; obtaining an optimal threshold according to the semantic similarity score, and screening out an index set; clustering the visual representation vectors of the blocks in the index set, and selecting the block with the highest semantic similarity score in each cluster as a representative block to obtain the index set; and based on the index set, extracting a feature matrix of each representative block, and backtracking to a space coordinate position of each representative block in the corresponding lung image data through an index to obtain a region of interest. Self-adaptive threshold filtering and recognition are carried out according to the semantic similarity score, and heterogeneity distribution of different wettability characteristics in the slice is reserved in the selected region of interest.

Provided are methods and systems for measuring lung function, such as shunt and deadspace, using pulmonary gas exchange in management and treatment of pulmonary diseases including COVID-19.

The application belongs to the field of digital medicine, and particularly relates to a chronic obstructive pulmonary disease (COPD) differential system based on digital lung sound, a construction method and application thereof. The system comprises a data acquisition module, a preprocessing module, a conversion module, a data module, a data processing module, a data enhancement training module, a deep learning module, a differential module, a grading module and a display module. Digital lung sound records of candidates are collected, converted into mel spectrograms, and diagnosed by using a deep neural network. The candidates are COPD patients, healthy people, or people suffering from other lung diseases, and the disease grade of the COPD patients is given by a device carrying the differential system. The examination only needs to collect lung sounds in clinical or other places, reduces radiation damage and possible infection risk in the conventional diagnosis process, and provides a scheme for early diagnosis of COPD, and improves the diagnosis efficiency of the respiratory department, especially the COPD disease.

This invention provides an application of the peptide Nod-T3 in the preparation of drugs for treating lung diseases. The Nod-T3 peptide is derived from human protein and has a significant inhibitory effect on chronic lung inflammation and fibrosis caused by smoking. It can be used to treat COPD and other smoking-related lung diseases. It also has high biocompatibility and low toxicity, and has the potential and development value to become a new type of peptide drug.

IL33 antagonists, alone or in combination with IL-4R antagonists, can be used to treat or inhibit eosinophilic asthma, eosinophilic COPD, eosinophilic ACOS, and nasal polyps in subjects having one or more risk alleles in intronic IL1RL1 variant rs1420101, in IL33 variant rs1342326, in both, or in variants in linkage disequilibrium therewith.

Disclosed herein are methods, compounds, and compositions for treating or preventing an inflammasome-mediated disease or condition, including an inflammasome-mediated pulmonary disease or condition.

The present disclosure relates to the detection of acute respiratory distress syndrome in a patient. Subjects of the present disclosure are a computer system, a method and a computer program product for detection of acute respiratory distress syndrome.

The present disclosure provides a variant AAV capsid protein that confers tropism to lung cells and recombinant adeno-associated viruses comprising the variant AAV capsid protein and pharmaceutical compositions comprising same and their use in the delivery of heterologous nucleic acids to lung cells for the treatment of pulmonary disorders.

The present disclosure relates to a pharmaceutical composition comprising an inhalable immunosuppressive macrocyclic active ingredient for use in the prevention or treatment of a pulmonary disease or condition in a subject, wherein the pharmaceutical composition is administered to the subject by inhalation in the form of an aerosol, and wherein the aerosol is produced by nebulizing the pharmaceutical composition using a nebulizer (100), which nebulizer comprises: a) an aerosol generator (101) comprising: - a fluid reservoir (103) for holding the pharmaceutical composition or an interface configured to connect a fluid reservoir, and a vibrating membrane (110) with a plurality of apertures, which apertures are adapted to produce an aerosol comprising droplets having a mass median aerodynamic diameter (MMAD) of up to about 4.0 gm as measured with aqueous 0,9% (w / v) sodium chloride solution; b) a chamber (105) for temporarily receiving the aerosol produced by the aerosol generator (101), wherein the chamber has an internal lumen with a volume in the range of about 50 to about 150 ml; and c) a mouthpiece (40) for delivering the aerosol provided by the nebulizer (100) to the subject, wherein the mouthpiece has an exhalation filter (30).,

In some aspects, the invention teaches pharmaceutical compositions that include a TGF-β ligand trap, and methods of using a TGF-β ligand trap to treat, prevent, or reduce the progression rate of pulmonary hypertension (PH). The invention also provides methods of using a TGF-β ligand trap to treat, prevent, or reduce the progression rate of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-β signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using a TGF-β ligand trap to reduce right ventricular systolic pressure in a subject.

The present invention relates to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione or one of its pharmaceutically acceptable salts in the treatment of rare chronic inflammatory pulmonary diseases. The invention in particular relates to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione sodium salt for said purposes.

Modulators of extracellular signal-regulated kinase, pharmaceutical compositions thereof, and uses of the compound and pharmaceutical compositions thereof for treating cancer and pulmonary diseases are disclosed.

The application discloses a kind of X-ray film lung disease screening systems of fusing multi-level features, including lung parenchyma segmentation module, lung disease preliminary screening module, multi-level feature construction module, lung disease screening module;Lung parenchyma segmentation module is used to obtain lung parenchyma part from complete chest X-ray film segmentation;Lung disease preliminary screening module is used to construct based on feature consistency variation auto-encoding generation adversarial network and train it, and obtains preliminary screening abnormal score using trained generation adversarial network;Multi-level feature construction module is used to extract features of different semantic levels, including the extraction of bottom visual features, middle layer depth features and high layer experience features;Lung disease screening module is used to construct lung disease screening model using multi-level features and the abnormal score obtained by lung disease preliminary screening module, and obtains the final lung disease classification result.The present application can effectively solve the problem that current computer-aided lung disease screening field research is difficult to be applied to practical clinical scene.

FIELD: molecular biology.SUBSTANCE: method for predicting a high risk of adverse outcome in a patient with purulent lung disease (PLD) infected with gram-negative bacteria of the Klebsiella pneumoniae species is described. The method involves isolating DNA from peripheral venous blood and determining variants of the AQP4 rs1058424 gene. When the AQP4 rs1058424 AA genotype is detected in a patient with PLD and the presence of signs of Klebsiella pneumoniae infection, a high risk of death is determined.EFFECT: based on the determination of the AQP4 rs1058424 genotype for patients with PLD and identified gram-negative bacteria, it becomes possible to fairly early divide hospitalized patients with purulent infection into high-risk and low-risk groups for a fatal outcome.1 cl, 4 ex

The application discloses application of phenyllactic acid or a composition containing phenyllactic acid in preparation of a drug for relieving lung diseases, wherein the lung diseases are preferably pulmonary fibrosis or acute lung injury. In an acute lung injury research model, the phenyllactic acid can effectively intervene in an inflammatory factor cascade reaction and an oxidative stress damage process, and significantly improve symptoms of acute lung injury caused by the above factors. Compared with a traditional treatment method, experiments prove that the phenyllactic acid or the composition containing the phenyllactic acid can significantly relieve symptoms of acute lung injury (ALI) of a mouse induced by lipopolysaccharide (LPS) and pulmonary fibrosis (PF) of the mouse induced by bleomycin, effectively improve pathological changes of the lung, and restore lung function.

The invention discloses an iRGD-modified mesenchymal stem cell outer vesicle-loaded WZ35 dual-targeting drug delivery composition, which is characterized in that rat bone marrow mesenchymal stem cell-derived extracellular vesicles are used as carriers, curcumin analogues WZ35 are loaded in the carriers, and iRGD peptides are covalently modified on the surfaces of the carriers, so that passive targeting and active targeting synergistic delivery is realized; efficient entrapment of the medicine is achieved in an extrusion or co-incubation mode, the particle size of the obtained composition is 100-200 nm, and the dispersity is good; in-vivo experiments show that compared with free WZ35, the composition has the advantages that the enrichment efficiency of WZ35 in lung tissue is remarkably improved, right ventricular systolic pressure can be effectively reduced in an anoxia-induced pulmonary arterial hypertension rat model, pulmonary vascular remodeling is improved, and the invention provides a novel efficient and safe drug delivery strategy for targeted therapy of lung diseases.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

The invention relates to compounds of formula (I) inhibiting Rho Kinase that are dihydrofuropyridine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).

Provided herein are compositions and methods for treating and preventing lung disease. In particular, provided herein are SP-A peptides and uses thereof in the treatment and prevention of lung disease (e.g., asthma or COPD).

The invention discloses an engineered polypeptide injection system and application thereof in targeted delivery of antibacterial peptides, and belongs to the technical field of biology. The engineered polypeptide injection system provided by the invention can accurately deliver the target polypeptide to a targeted infection site, reduce whole body exposure, reduce toxicity and give full play to the effect of the target polypeptide. The invention also provides application of the engineered polypeptide injection system in preparation of a product for eliminating mycobacteria in target cells and preparation of a product for preventing and / or treating lung diseases and / or symptoms caused by the mycobacteria, and target polypeptides Granulysin, HNP1, and LysA and / or LysB derived from mycobacteriophage D29 or MS6 are delivered to macrophages, so that the lung diseases and / or symptoms caused by the mycobacteria are prevented and treated, and the lung diseases and / or symptoms caused by the mycobacteria are prevented and treated. The mycobacteria can be effectively removed.

A respiration monitoring device comprises an electronic controller configured to: receive an audio signal that is acoustically coupled with an airway of a patient receiving mechanical ventilation therapy from a mechanical ventilator; map the audio signal to one or more lung disease or injury condition categories; and at least one of: display the mapped one or more lung disease or injury condition categories on a display device; and determine a recommended adjustment to one or more parameters of the mechanical ventilation therapy delivered to the patient based at least on the mapped lung disease or injury condition categories and displaying the recommended adjustment on the display device.

The invention discloses a novel application of hederagenin in preparation of a medicine for maintaining the dryness of alveolar II epithelial cells, the hederagenin is definitely used for preparing the medicine for maintaining the dryness of the alveolar II epithelial cells for the first time, and the repairing effect of the hederagenin on ATII dry damage is verified through in-vivo and in-vitro experiments. A brand new treatment strategy is provided for lung diseases such as acute lung injury, pulmonary fibrosis and the like which are characterized by ATII dry failure, the technical blank of intervention of natural active ingredients in ATII dry is filled up, a new way which is efficient, low in cost and easy to obtain is provided for ATII dry maintenance, the concentration of a medicine prepared from the natural active ingredients is screened, and the clinical application prospect is wide. An important theoretical basis is provided for further medication and medicine preparation, meanwhile, the pharmacological application range of the hederagenin is expanded, and a new target and a new strategy are provided for subsequent intervention treatment of lung diseases such as acute lung injury and pulmonary fibrosis needing injury repair.

A machine learning approach is herein provided for preparing a model for assessing the progression of a lung disease, comprises receiving a first set of segmented images of lungs from different patients with the lung disease. The first set of images is segmented and used to train the model. The trained model is applied to a set of unsegmented images to generate a second set of segmented images. The model is updated with the second set of segmented segmentation. From the model, at least one result associated with progression of the lung disease is outputted.

The invention belongs to the technical field of micro-fluidic chips, and provides a micro-fluidic lung chip for simulating child lung physiological characteristics, and particularly aims at simulating specific respiratory frequencies of children at different growth stages, simulating a tissue barrier interface of pulmonary epithelium and endothelium, and simulating a fluid microenvironment. The micro-fluidic chip is mainly composed of two layers of micro-channels, the channels are separated by a polydimethylsiloxane porous membrane, two sides of each channel are respectively provided with a vacuum cavity, each layer of channel is provided with an inlet and an outlet, and a dynamic environment is formed through fluid. Lung epithelial cells and endothelial cells are respectively inoculated in the upper channel and the lower channel on the chip to form an alveolar-capillary interface on the chip. By applying negative pressure to the vacuum cavity, the respiratory frequencies of children in different growth stages are simulated. The invention provides a multi-factor participated tissue level research system for children lung diseases and children medicine research.

This invention relates to a biomarker, reagent, kit, and detection system for the diagnosis of lung diseases. The biomarker for detecting lung diseases is exosome-derived miRNA, including at least one of miR-143-3p, miR-103a-3p, miR-92a-3p, miR-223-3p, miR-363-3p, miR-199b-3p, miR-16-5p, miR-155-5p, miR-122-5p, miR-483-5p, Let-7c-5p, miR-486-5p, miR-192-5p, miR-20a-5p, miR-221-3p, miR-21-5p, and miR-30e-5p. Lung diseases are diagnosed by detecting the expression of these miRNAs. The above-mentioned biomarker for detecting lung diseases has high accuracy in diagnosing benign and malignant pulmonary nodules.

A novel CHI3L1 inhibitor provided in the present invention can efficiently inhibit or treat disease progression of nontuberculous mycobacteria-infected lung diseases by inhibiting CHI3L1. In particular, it has been identified that K284-6111 can inhibit or treat disease progression of nontuberculous mycobacteria-infected lung diseases by inhibiting CHI3L1, and by newly synthesizing derivatives of K284-6111, novel compounds having a CHI3L1 inhibitory ability superior to that of K284-6111 have been identified. Therefore, the novel CHI3L1 inhibitors provided in the present invention can inhibit or treat disease progression of nontuberculous mycobacteria-infected lung diseases by inhibiting CHI3L1.

The invention discloses a deuterated tetracyclic derivative and application of the deuterated tetracyclic derivative in prevention or treatment of diseases caused by bacterial infection, and particularly application of the deuterated tetracyclic derivative in prevention or treatment of lung diseases caused by mycobacterium tuberculosis or drug-resistant mycobacterium tuberculosis.

The present invention provides methods for treating inflammatory diseases, or conditions associated with, or resulting in part from, elevated levels of IL-33 and IL-4, in particular inflammatory lung disorders. The methods of the present invention comprise administering to a subject in need thereof one or more therapeutically effective doses of an IL-33 antagonist alone or in combination with one or more therapeutically effective doses of an IL-4R antagonist. In certain embodiments, the methods of the present invention include use of the antagonists to treat any inflammatory disease or condition mediated in part by enhanced IL-33-mediated signaling and IL-4-mediated signaling.